Physician profile
Mitchell C Shultz
NPI 1427153022
$524,364.75
in general payments reported to CMS, 2019-2025
38 companies · $135K in 2025
The $135K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $97K · 2020: $11K · 2021: $68K · 2022: $78K · 2023: $37K · 2024: $98K · 2025: $135K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $132K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $54K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Food and Beverage: $20K · Travel and Lodging: $18K · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $131,833.67 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $53,875.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,850.00 |
| Food and Beverage | $20,349.71 |
| Travel and Lodging | $17,742.01 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $173,201.57 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $150,177.77 | 2019-2021 | |
| Glaukos Corporation | $64,919.12 | 2019-2025 | Idose, Ce-Marked Kxla System, Istent Trabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $43,858.15 | 2024-2025 | Xdemvy |
| Beaver-Visitec International, INC. | $22,960.00 | 2022-2023 | |
| Alcon Vision LLC | $15,499.47 | 2019-2025 | Tryptyr, Hydrus Microstent, Clareon Panoptix Pro |
| Sight Sciences, INC. | $9,225.59 | 2021-2025 | Omni Surgical System |
| Ivantis, INC | $6,679.14 | 2019-2021 | |
| Abbvie INC. | $6,552.11 | 2022-2025 | Vuity, Durysta, Lumigan |
| Nova Eye, INC. | $5,621.44 | 2024-2025 | |
| New World Medical,INC. | $4,103.91 | 2020-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Lensar, INC. | $3,347.62 | 2023 | Lensar Laser System |
| Nordic Pharma, INC. | $3,214.92 | 2025 | Lacrifill |
| Harrow Eye, LLC | $2,046.02 | 2024-2025 | Vevye, Triesence |
| Sun Pharmaceutical Industries INC. | $2,038.12 | 2020-2025 | Cequa, Xelpros, Bromsite |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $1,900.42 | 2022-2025 | Tyrvaya |
| Allergan, INC. | $1,836.51 | 2019-2022 | |
| Carl Zeiss Meditec USA, INC. | $1,041.06 | 2021-2024 | Quatera 700, Atlas 500, Iolmaster 700 |
| Tearlab Corp | $1,023.30 | 2023-2024 | Scoutpro Osmolarity System, Tearlab Osmolarity System |
| Johnson & Johnson Surgical Vision, INC. | $920.90 | 2021-2024 | Catalys System, Tecnis Iol, Tecnis Simplicity |
| Lumenis Be INC | $774.40 | 2023-2025 | M22 |
| Rxsight INC | $748.90 | 2021-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Bausch Health US, LLC | $718.28 | 2019-2021 | |
| Ellexiscience | $395.21 | 2019 | |
| Carl Zeiss Meditec, INC. | $358.37 | 2019-2023 | Callisto Eye, Veracity Surgical, Artevo 800 |
| Dompe US, INC. | $241.47 | 2021-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $223.97 | 2021-2023 | |
| Eyepoint US, INC. | $143.94 | 2019 | |
| Amgen INC. | $122.32 | 2024-2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $105.55 | 2019-2023 | Flarex |
| Aerie Pharmaceuticals, INC. | $85.62 | 2020-2021 | |
| Omeros Corporation | $62.64 | 2019-2020 | |
| Horizon Therapeutics Plc | $60.97 | 2022-2023 | Tepezza |
| Thea Pharma INC. | $42.34 | 2024-2025 | Iyuzeh |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Kala Pharmaceuticals, INC. | $38.31 | 2020-2021 | |
| Ocular Therapeutix, INC. | $36.52 | 2022-2025 | Dextenza |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$306,490.50 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Shultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.